9885.HK

Pharmaceutical e-commerce platform YSB Inc. (9885.HK) announced on Thursday that it expects to record a net profit of 70 million yuan ($9.75 million) or more for the six months through June, more than triple the 21.8 million yuan it reported a year earlier.

The company credited the surge to steady revenue growth, strong demand for its high-margin self-branded products, and enhanced digital capabilities that improved the efficiency of its platform and direct-sales operations.

YSB‘s stock opened higher on Friday but later turn lower, closing at HK$10.02 by the midday break, down 2.34%. The stock is up 67.9% this year.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Damai sells concert tickets

Damai rides China’s offline leisure boom to bumper profits

The company’s dominance in live entertainment ticketing and IP franchises has turbocharged its revenue, despite persistent consumer complaints and monopolistic behavior Key Takeaways: Damai’s profit rose around 50% in the…